Drugs / Ciprodex

Regulatory milestones approvals, filings & regulatory actions · 1 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Approved US (FDA) CIPRODEX 2003-07-18 fda.gov

Trials 1 · a red edge is where a trial was stopped

today
US approved 2003
NCT00956748 · Ph 4
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 4 NCT00956748 Nov 2019 discharging ear, otitis media St. Paul's Hospital, Canada Withdrawn No outcome recorded
Also used as a comparator or background therapy in 2 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 31 trial
Phase 3 NCT00961675 Comparator Aug 2009 → Jun 2010 acute otitis externa Shire Completed No outcome recorded
Phase 41 trial
Phase 4 NCT03347461 Comparator Oct 2018 → Jun 2019 discharging ear, otitis media with effusion Boston Medical Center Withdrawn No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as Ciprodex ClinicalTrials.gov intervention name — accepted as the source's own label NCT00961675
2

NCT00956748

NCT03347461

Known as CIPRODEX (ciprofloxacin 0.3% and dexamethasone 0.1%) Sterile Otic Suspension “CIPRODEX® (ciprofloxacin 0.3% and dexamethasone 0.1%) Sterile Otic Suspension” NCT00961675
Route Topical “ciprofloxacin 0.3% / dexamethasone 0.1% otic solution” NCT00956748